Category: Pharma & Biotech

Vitality Biopharma CEO Robert Brooke Provides Shareholder Letter

LOS ANGELES, March 19, 2018 (GLOBE NEWSWIRE) — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise of a letter issued to Company shareholders. “As we’re poised to enter a new phase of our company’s development, it’s exciting to reflect on the work that has enabled this,” said Robert Brooke, CEO and Co-Founder of Vitality Biopharma. “It provides a glimpse into our organization and the components of our drug development program that we’ve been advancing in parallel. Our R&D team also continues to innovate, achieving recent breakthroughs in biosynthesis and biomanufacturing, and developing entirely new therapeutic applications for cannabinoids. Ultimately, 2018 is sure to be a momentous year for Vitality and I hope shareholders will now better understand why.” The shareholder letter describes Vitality Biopharma’s cannabinoid drug development portfolio and achievements such as DEA approval that are necessary in order for the Company to conduct its R&D operations and cannabinoid drug manufacturing in the United States. The shareholder letter includes separate sections describing: – The potential for expedited regulatory development and FDA approvals; – Cannabinoid biosynthesis and production breakthroughs; – Introduction of the VBX class of drug formulations, and Vitality’s lead drug candidate VBX-100; – Positive preclinical results, including new...

Read More

True Leaf Announces Cannabis Cultivation Team Experts in genetics and cultivation will lead the development of high-quality medicinal cannabis products at True Leaf Campus

Vernon, British Columbia- (Newsfile Corp. – March 19, 2018) – True Leaf Medicine International Ltd. (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) (“True Leaf”), the quality of life cannabis company for people and their pets, has recruited two medicinal cannabis cultivation experts to lead the development of its medicinal cannabis products. Stephen Schroeder, Chief Cannabis Industry Advisor, and Christian Zofchak, Director of Horticulture Operations, have joined the True Leaf team, driven by a motivation to help patients, as well as their own family members, who find their pharmaceutical treatments ineffective or intolerable. “True Leaf is assembling a world-class team of medical, genetics and cultivation experts,” said Darcy Bomford, Founder and Chief Executive Officer of True Leaf. “Our mission is to be Canada’s leading purpose-driven cannabis company, so we are proud to announce today Stephen and Christian will be creating high-quality medical products for people and their pets here at True Leaf Campus.” The cultivation team members are Canadian leaders in selective cannabis plant development. They will identify the best cannabis plant genetics worldwide, and, as part of True Leaf’s proprietary intellectual property, will develop unique strains capable of producing the active ingredients needed to develop a highly-effective medicinal product line to address neurological, musculoskeletal, gynaecological, and gastrointestinal conditions. Mr. Schroeder has overseen millions of square feet of cannabis cultivation worldwide. Now anOkanagan Valley resident, he has consulted on cannabis operations...

Read More

Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.

OTTAWA, ONTARIO–(Marketwired – March 19, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction”) from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Sellers”). “The Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO. “It allows Tetra to gain 100% control of PhytoPain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives Tetra full flexibility to enter into other partnerships or agreements in the future.” The purchase price for the Transaction was comprised of a combination of cash, promissory notes and common shares of Tetra, some of which will be released to the Sellers upon the achievement of key milestones. The terms of the Transaction are detailed in the Corporation’s news release dated January 2, 2018 which is available on SEDAR under the Corporation’s profile. The Corporation used $500,000 out of the proceeds from the recently completed bought deal offering to repay a portion of the principal amount owing to the Sellers under the promissory notes. About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development....

Read More

Pivot Pharmaceutials Named to Canadian Securities Exchange’s CSE25 Index

VANCOUVER, March 19, 2018 /CNW/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”), is pleased to announce that effective March 16th, 2018 the Company has been named to the CSE25 Index, a composite of the 25 largest companies, as measured by market capitalization, listed on the Canadian Securities Exchange. In addition, the Company is also a constituent of the CSE Composite Index. “With an impressive pipeline of bio-cannabis products, a strong intellectual property portfolio of formulation and delivery technologies, and the expected addition of ACMPR licensed Agro-Biotech, we are proud to be recognized as leaders on the Canadian Securities Exchange through our inclusion in the CSE25 Index,” said Dr. Patrick Frankham, Chief Executive Officer of Pivot Pharmaceuticals. “Being among the top 25 performers on the exchange validates our business strategy to become a vertically integrated health and wellness company with a rapidly expanding international presence. With all of the exciting opportunities ahead of us, we believe we will remain a consistent part of the CSE25 Index for years to come as we continue to drive shareholder value.” About Pivot Pharmaceuticals Inc. Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green...

Read More

INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline

PHOENIX, March 19, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement: The company continues striving to take responsibility for inappropriate actions of some former employees and has invested significant resources over the last several years to establish an effective compliance program and build an organizational culture of high ethical standards. Intending to learn from past events, we also continue working with relevant authorities to resolve issues related to inappropriate actions taken by former employees. Last week’s federal indictments of five New York physicians involve allegations related to former employees. We understand that in addition to taking responsibility for former employees’ actions, the best ways to exhibit our desire to be a valued member of the healthcare community are to: • focus on the actions of current employees and reinforce an organizational culture of high ethical standards; • remain firmly committed to operating the business with a strong focus on the best interests of patients; and • continue investing in innovating new treatment options for serious unmet patient needs. We believe our actions over the last several years, including our significant investment in R&D programs, illustrate our commitment to these priorities and the company’s future. About INSYS INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and...

Read More

AXIM Biotechnologies Reports Year End 2017 Results

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced financial results for the quarter and year ended December 31, 2017, and provided an overview of recent operational highlights “During the year, we continued to make solid progress with our clinical pipeline of cannabinoid products. We moved forward to develop a dronabinol-based functional, controlled-release chewing gum product bioequivalent to Marinol® to help treat patients with chemotherapy induced nausea and vomiting and AIDS patients experiencing appetite and weight loss. Our product development partner obtained the licenses to import and work with controlled drugs that are required to continue the development of MedChew Rx® pharmaceutical chewing gum to treat pain and spasticity associated with multiple sclerosis (MS). We achieved encouraging clinical trial results from our phase IIA pilot trial for the treatment of irritable bowel syndrome (IBS) with our CanChew +® 50 mg CBD (cannabidiol) functional, controlled release chewing gum,” said Dr. George Anastassov, MD, DDS, MBA and CEO of AXIM Biotechnologies. “In addition, we received two new patent allowances for cannabinoids-based ophthalmic solutions for the treatment of glaucoma and symptomatic relief of conjunctival inflammation, and announced the filing of a new patent of a chewing gum with controlled release of cannabinoids and opioid agonists and antagonists for treatment of opioid addiction and cannabis dependence. We are...

Read More
  • 1
  • 2